Document Type

Journal Article

Authors

Atik Badshah Shaikh, Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist UniversityFollow
Fangfei Li, Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist UniversityFollow
Min Li, Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist UniversityFollow
Bing He, Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist UniversityFollow
Xiaojuan He, Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist UniversityFollow
Guofen Chen, Orthopaedic Surgery Department, Nanfang Hospital, Southern Medical University
Baosheng Guo, Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist UniversityFollow
Defang Li, Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist UniversityFollow
Feng Jiang, Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist UniversityFollow
Lei Dang, Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist UniversityFollow
Shaowei Zheng, Department of Orthopaedic Surgery, The First Hospital of Huizhou
Chao Liang, Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist UniversityFollow
Jin Liu, Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist UniversityFollow
Cheng Lu, Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist UniversityFollow
Biao Liu, Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist UniversityFollow
Jun Lu, Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist UniversityFollow
Luyao Wang, Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist UniversityFollow
Aiping Lu, Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist UniversityFollow
Ge Zhang, Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist UniversityFollow

Department/Unit

School of Chinese Medicine

Abstract

© 2016 by the authors; licensee MDPI, Basel, Switzerland. Osteosarcoma (OS) is a bone cancer mostly occurring in pediatric population. Current treatment regime of surgery and intensive chemotherapy could cure about 60%–75% patients with primary osteosarcoma, however only 15% to 30% can be cured when pulmonary metastasis or relapse has taken place. Hence, novel precise OS-targeting therapies are being developed with the hope of addressing this issue. This review summarizes the current development of molecular mechanisms and targets for osteosarcoma. Therapies that target these mechanisms with updated information on clinical trials are also reviewed. Meanwhile, we further discuss novel therapeutic targets and OS-targeting drug delivery systems. In conclusion, a full insight in OS pathogenesis and OS-targeting strategies would help us explore novel targeted therapies for metastatic osteosarcoma.

Publication Year

2016

Journal Title

International Journal of Molecular Sciences

Volume number

4

Issue number

17

Publisher

MDPI

Referreed

1

DOI

10.3390/ijms17040506

ISSN (print)

16616596

Keywords

Molecular mechanism, Molecular targets, Osteosarcoma, Targeted therapy

Share

COinS